These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29568090)

  • 1. IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.
    Meggendorfer M; Cappelli LV; Walter W; Haferlach C; Kern W; Falini B; Haferlach T
    Leukemia; 2018 May; 32(5):1249-1253. PubMed ID: 29568090
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Qin Y; Shen K; Liu T; Ma H
    BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (2
    Idle JR; Seipel K; Bacher U; Pabst T; Beyoğlu D
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33019704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
    Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of isocitrate dehydrogenase mutant AML.
    Boddu P; Borthakur G
    Expert Opin Investig Drugs; 2017 May; 26(5):525-530. PubMed ID: 28388242
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel Therapeutics in Acute Myeloid Leukemia.
    DiNardo CD; Stone RM; Medeiros BC
    Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
    Ravandi F; Patel K; Luthra R; Faderl S; Konopleva M; Kadia T; Brandt M; Pierce S; Kornblau S; Andreeff M; Wang X; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2012 May; 118(10):2665-73. PubMed ID: 22020636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets.
    Brower V
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26864927
    [No Abstract]   [Full Text] [Related]  

  • 9. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
    Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
    Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical relevance of
    Ferret Y; Boissel N; Helevaut N; Madic J; Nibourel O; Marceau-Renaut A; Bucci M; Geffroy S; Celli-Lebras K; Castaigne S; Thomas X; Terré C; Dombret H; Preudhomme C; Renneville A
    Haematologica; 2018 May; 103(5):822-829. PubMed ID: 29472349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors for acute myeloid leukemia: where is the field heading?
    Trippier PC
    Future Med Chem; 2017 Sep; 9(13):1453-1456. PubMed ID: 28795593
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecularly targeted therapies for acute myeloid leukemia.
    Stein EM
    Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
    DiNardo C; Lachowiez C
    Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for optimism in the therapy of acute leukemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2015; 28(2-3):69-72. PubMed ID: 26590761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
    DiNardo C
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078
    [No Abstract]   [Full Text] [Related]  

  • 18. Updates on DNA methylation modifiers in acute myeloid leukemia.
    Contieri B; Duarte BKL; Lazarini M
    Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [FLT3 inhibitors for acute myeloid leukemia].
    Kiyoi H
    Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
    DiNardo CD; Stein EM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.